Therapeutic effect of a single peritumoural dose of IL-2 on transplanted murine breast cancer

Abstract

Interleukin-2 therapy is not clearly effective against breast cancer both in mouse models and in human patients. However, the study of IL-2 therapy of breast cancer remains important, as 3,700 women died from this malignancy in the Netherlands in 2000. Previously we have shown the therapeutical efficacy of a single peritumoural IL-2 application in different experimental models and in veterinary patients. Here we apply this mode of IL-2 therapy to advanced mouse mammary carcinoma models, i.e., severe metastasised tumours in A/Sn mice and non-metastasised carcinomas in BALB/c mice. Mice with advanced transplanted mammary carcinomas were given a single peritumoural treatment with 2.5 x 10(6) IU IL-2 at days 10-14 after i.p. or s.c. inoculation of 10(6) carcinoma cells. Within each experiment it was always possible to distinguish relatively slowly and fast growing tumours which allows the therapeutical effect of IL-2 in tumours with different growth rates to be studied. A new approach to analyse results enabled us to show that survival of mice with transplanted, advanced metastasised breast cancer can be significantly improved after a single local treatment with IL-2. Advanced relatively fast i.p and s.c. growing mammary carcinomas seem to be more sensitive to a single IL-2 treatment than relatively slowly growing tumours. IL-2 was most effective against non-metastasised mouse breast cancer.

Evaluation of antitumor activity of peptide extracts from medicinal plants on the model of transplanted breast cancer in CBRB-Rb(8.17)1Iem mice

“…Recipients received 10 6 tumor cells of slowly growing spontaneous mammary adenocarcinoma obtained from syngeneic females as described previously [6]. On the next day after transplantation, experimental animals received single injection of plant peptide extracts (1 mg in 0.1 ml saline) to the site of transplantation.…”

“…Three perpendicular sizes of the tumor were measured and its mean diameter was calculated from these values for each recipient [6]. The results were evaluated using Student's t test.…”

Potential prognostic and therapeutic roles for cytokines in breast cancer (Review)

“…melanoma, pulmonary metastasis of renal carcinoma, unresectable pancreatic head carcinoma and malignant mesothelioma. In contrast, IL-2 therapy for breast cancer has not been generally effective although, recently, peri-tumoural administration of IL-2 was reported to significantly improve survival in mice with advanced and relatively aggressive tumours (45). Furthermore, in a phase-I trial with HER2-overexpressing metastatic breast cancer, Repka and colleagues (46) reported encouraging results when Trastuzumab was used in combination with IL-2.…”

Galectins as markers of aggressiveness of mouse mammary carcinoma: towards a lectin target therapy of human breast cancer

“…Finally, the entire complex of inherent attributes of human BC is hardly reproduced in one mouse strain/model. Hence, we developed a system of mouse models with different characteristics and natural incidences of mammary cancer to reproduce various forms of human BC [20][21][22]. Recently, we have reported about our mouse models as appropriate tools to test alternative novel modes of anti-BC therapy [8,21,22].…”

“…Hence, we developed a system of mouse models with different characteristics and natural incidences of mammary cancer to reproduce various forms of human BC [20][21][22]. Recently, we have reported about our mouse models as appropriate tools to test alternative novel modes of anti-BC therapy [8,21,22]. Transplantable aggressive mouse mammary carcinoma in A/Sn mice demonstrated high metastatic spread to liver, spleen, kidney, and lymph nodes comparable with human BC [21].…”